Prothena Corp. (PRTA) Posts Smaller Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
Prothena Reports Fourth Quarter and Full Year 2018 Financial Results, and Provides Financial Guidance and R&D Update
February 14, 2019 4:05 PM ESTNet cash used in operating and investing activities was $22.5 million in the fourth quarter and $30.0 million for the full year 2018; quarter-end cash and restricted cash position of $431.7 million provides funding to advance neuroscience pipeline Entered into global neuroscience research & development collaboration with Celgene to advance novel therapies for patients with neurodegenerative diseasesInitiated a first-in-human study of PRX004 in patients with ATTR amyloidosisEnrollment completed for the Phase 2 PASADENA study of prasinezumab in patients with early Parkinsons disease
DUBLIN, Ireland, Feb. 14,... More
